Investing.com - Assertio Therapeutics reported on Tuesday third quarter earnings that beat analysts' forecasts and revenue that topped expectations.
Assertio Therapeutics announced earnings per share of $0.2200 on revenue of $34.28M. Analysts polled by Investing.com anticipated EPS of $0.0905 on revenue of $32.01M.
Assertio Therapeutics shares are down 16% from the beginning of the year , still down 40.99% from its 52 week high of $4.44 set on Monday, August 8, 2022.
Assertio Therapeutics follows other major Healthcare sector earnings this month
Assertio Therapeutics's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar